New drug price negotiations under the Inflation Reduction Act are underway.
3 reports, 3 independent
Updated Jul 8
Gone quiet
- Reports
- 3
- Developments
- 4
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
New drug price negotiations under the Inflation Reduction Act are underway.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The Inflation Reduction Act's drug price negotiations are causing sales headwinds for an unnamed company.Sub-event
- AARP advocated for Medicare to negotiate drug prices in Washington, D.C.Sub-event
CMS is revising rules governing drug price negotiations.1 source
New drug price negotiations under the Inflation Reduction Act.1 source
Keep exploring
The entities involved
-
Medicare
US federal health insurance
Related events
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- Trump promised drug discounts for low-income Americans and discussed Pfizer deals at a Dallas convention.
- Tariffs are introducing uncertainty into the drug market structure.
- Federal legislation capped high-cost drug prices while market projections missed and Supreme Court ruled on import tax authority.
- Administration proposes a rule to manage Medicare drug costs, reported by the Associated Press.